Search research articles
Contact Us
Filters
Showing results (121-130 of 183) with videos related to
Page
of 19
Sort By:
The New England Journal of Medicine
|
September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Aditya Bardia, Xichun Hu, Rebecca Dent, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC
Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 12, 2011
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
F Saad, J E Brown, C Van Poznak, et al.
The New England Journal of Medicine
|
July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Javier Cortes, Hope S Rugo, David W Cescon, et al.
Lancet (London, England)
|
December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes, David W Cescon, Hope S Rugo, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Journal of the National Cancer Institute
|
December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
David W Cescon, Peter Schmid, Hope S Rugo, et al.
Clinical Breast Cancer
|
December 9, 2015
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Henry L Gómez, Silvia Neciosup, Célia Tosello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2018
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 183) with videos related to
Sort By:
Page
of 19
The New England Journal of Medicine
|
September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Aditya Bardia, Xichun Hu, Rebecca Dent, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC
Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 12, 2011
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
F Saad, J E Brown, C Van Poznak, et al.
The New England Journal of Medicine
|
July 20, 2022
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Javier Cortes, Hope S Rugo, David W Cescon, et al.
Lancet (London, England)
|
December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes, David W Cescon, Hope S Rugo, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Journal of the National Cancer Institute
|
December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
David W Cescon, Peter Schmid, Hope S Rugo, et al.
Clinical Breast Cancer
|
December 9, 2015
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Henry L Gómez, Silvia Neciosup, Célia Tosello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2018
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox, C H Barrios, T M Kim, et al.
Page
of 19